Peptide therapy TikTok claims: what the science actually supports

What did @steven actually say?

This video is a two-person interview format where the host asks a peptide advocate to walk through what peptides can do for your health. The guest's framing: "the question isn't what can peptides do, it's what can't they do." He name-drops GLP-1s for weight loss, GHK-Cu for skin, BPC-157 for gut health and ulcerative colitis specifically, and unnamed peptides for sleep and pineal gland restoration. He wraps with a claim that pharmaceutical companies are quietly investing billions in peptide development while appearing to resist it publicly.

The app analogy is memorable. Peptides as software upgrades for the body. It's a good soundbite. But analogies aren't evidence, and this video is almost entirely analogy, brand names, and enthusiasm, with very little acknowledgment that most of what he's describing either lacks human trial data or is explicitly not approved for clinical use in humans.

Does the science back this up?

It depends heavily on which peptide you're asking about. GLP-1 receptor agonists like semaglutide? Yes, extensively studied and FDA-approved. The rest of the list? Much thinner. BPC-157 has interesting rodent data but zero completed human randomized controlled trials as of 2024. GHK-Cu has some in vitro and cosmetic research, but clinical evidence for systemic skin improvement is sparse.

The ulcerative colitis claim about BPC-157 is the most specific and the most concerning. Sikiric et al. have published extensively on BPC-157 in animal models, including gastrointestinal healing (Sikiric, 2018, Current Pharmaceutical Design), but these are rat studies. Extrapolating that to a human inflammatory bowel disease is a significant leap that most gastroenterologists would not make. The pineal gland and sleep claim is so vague it is essentially unfalsifiable, which is a problem in itself.

What did they get wrong (or right)?

Credit where it is due: the pharmaceutical industry investment point is accurate. Companies like Novo Nordisk and Eli Lilly have poured enormous capital into peptide pipelines, and AI-assisted peptide design is a real and growing field (Craik et al., 2013, Science; more recently reflected in Nature Biotechnology coverage of AI drug discovery in 2023). The guest is not wrong that peptide-based drugs are coming.

What he gets wrong, or at least dangerously incomplete: conflating FDA-approved peptide drugs with experimental, unregulated, compounded peptides is misleading. When he says "peptides that can heal your gut, like BPC-157, particularly effective in ulcerative colitis," he is presenting preclinical animal data as though it were established clinical fact. That is not accurate. BPC-157 is not FDA-approved for any condition. It was placed on the FDA's list of bulk drug substances that cannot be compounded in 2022, precisely because the evidence bar had not been met. Presenting it as "particularly effective" in a named human disease without that context is a material omission.

What should you actually know?

Peptides are a genuinely interesting and fast-moving area of medicine. The GLP-1 story alone has reshaped how we think about obesity and metabolic disease. But the legitimate science does not give blanket permission to assume every peptide someone sells or injects works the same way.

The regulatory landscape matters here. Several peptides discussed in this video category, including BPC-157 and TB-500 (thymosin beta-4), have faced FDA scrutiny specifically around compounding. Semax and selank are not approved in the US at all. MK-677 is not a peptide, it is a small molecule ghrelin mimetic, and calling it one is technically incorrect. These distinctions matter if you are a patient making decisions.

If you are curious about peptide therapy, the honest conversation starts with: which peptide, for what indication, with what evidence, prescribed by whom, and sourced from where. "What can't they do" is not a clinical framework. It is a marketing frame.

What's the bottom line?

This video blends real science with significant overreach. The enthusiasm is understandable, the evidence base is not as strong as the tone implies, and at least one specific claim, BPC-157 being "particularly effective" in ulcerative colitis, misrepresents the current state of human evidence. If you are considering peptide therapy for any condition, you need a clinician who knows the actual trial data, not just the optimistic version of it.